FREMONT, Calif., Feb. 27, 2017 /PRNewswire/ -- DiscoverX Corporation, the leading provider of innovative cell-based assays and services for drug discovery and development, announces the launch of their PathHunter® checkpoint receptor screening and profiling services, known as iONCscan, providing validated assays for characterizing the increasing number of new immuno-oncology targets. The iONCscan services for checkpoint receptors accelerate development of cancer immunotherapies by providing functional data within weeks using biologically-relevant cell-based assays, eliminating the variability and time consuming protocols experienced with traditional functional screening with primary cells.
iONCscan is an ideal tool during screening and lead optimization workflows for identifying qualified hits, performing potency evaluation, and rank ordering of candidate molecules. Designed to measure early events in receptor activation, the checkpoint assays have exceptional specificity and selectivity making them suitable for discovery of both small molecule and biologic drug candidates.
"This rapidly expanding portfolio from DiscoverX for the immuno-oncology market will enable researchers to take advantage of our extensive experience in screening and profiling large numbers of molecules, enabling the rapid prioritization of drug candidates," said Todd R. Nelson, Ph.D., CEO of DiscoverX. "With cell-based assays available for both stimulatory and inhibitory targets such as PD-1, CTLA4, CD137, and OX40, this service provides researchers an innovative option to test novel molecules with agility and specificity in their quest to find the next powerful immunotherapy treatment."
For more information on the PathHunter iONCscan services, visit discoverx.com.
DiscoverX Corporation, headquartered in Fremont, CA, USA, is a leader in the design, manufacture and sale of biochemical and cell-based assays for the drug discovery & life science markets. This industry-leading portfolio of products and services, under the KINOMEscan®, PathHunter® and BioMAP® brands, are used to aid life science research and enable rapid development of safe and effective biologic and small molecule drugs, by improving research productivity, effectiveness of screening, lead optimization & bioanalytical campaigns, as well as providing predictive tools that deliver physiologically relevant insights on drug molecules from early discovery through pre-clinical development. DiscoverX embodies an innovative approach to creating life science tools that have been widely adopted across the globe in pharmaceutical, biotechnology and academic laboratories. Learn more at discoverx.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rapidly-screen-molecules-for-novel-immuno-oncology-therapeutics-with-checkpoint-receptor-screening-and-profiling-services-300412938.html
SOURCE DiscoveRx Corporation